Public Employees Retirement Association of Colorado Has $14.45 Million Position in Insulet Corporation $PODD

Public Employees Retirement Association of Colorado boosted its holdings in Insulet Corporation (NASDAQ:PODD) by 643.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 50,840 shares of the medical instruments supplier’s stock after buying an additional 44,000 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Insulet were worth $14,451,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC raised its holdings in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the period. Elyxium Wealth LLC acquired a new stake in Insulet in the fourth quarter worth $28,000. Fideuram Asset Management Ireland dac acquired a new stake in Insulet in the fourth quarter worth $41,000. Measured Wealth Private Client Group LLC acquired a new stake in Insulet in the third quarter worth $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in Insulet in the second quarter worth $51,000.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PODD shares. William Blair started coverage on shares of Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating on the stock. Wells Fargo & Company cut their target price on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Barclays lowered their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Canaccord Genuity Group lowered their price objective on shares of Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $240.78.

Insulet Stock Down 1.0%

Insulet stock opened at $148.14 on Tuesday. The company has a market cap of $10.26 billion, a P/E ratio of 34.45, a price-to-earnings-growth ratio of 1.18 and a beta of 1.13. Insulet Corporation has a 1-year low of $140.63 and a 1-year high of $354.88. The company has a fifty day simple moving average of $168.80 and a 200 day simple moving average of $230.66. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.